As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
11 Analysts have issued a Kodiak Sciences, Inc. forecast:
11 Analysts have issued a Kodiak Sciences, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -189 -189 |
2%
2%
|
|
| EBIT (Operating Income) EBIT | -208 -208 |
2%
2%
|
|
| Net Profit | -200 -200 |
1%
1%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
| Head office | United States |
| CEO | Victor Perlroth |
| Employees | 121 |
| Founded | 2009 |
| Website | kodiak.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


